Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Jul 18, 2023 10:53am
88 Views
Post# 35545960

RE:Pfizer partners with startup Flagship valued at US$7 Billion

RE:Pfizer partners with startup Flagship valued at US$7 BillionShould read: July 18, 2023 - Pfizer and Flagship join forces on the hunt for new drugs.

" The collaboration involves Flagship’s “Pioneering Medicines” (early stage development) initiative, which has struck similarly structured deals in the recent past ..." 

"Flagship pitches (it's Pioneering Medicines Initiative)  as a way to tap into all the research those companies generate, pick out promising ideas they may not have time to develop and, potentially, advance them together with partners."  Another way of describing this initative is as an early exploration of yet-to-be determined targets for possible further pre-clinical development.

As cited in the below referenced link .. "Ever on the edge of “
patent cliffs,” big drugmakers like Pfizer routinely hunt for promising new drugs in the labs of smaller biotech companies."

"“Flagship and Pfizer enter into this strategic alliance driven by a shared sense of urgency to develop novel medicines that make a difference for patients,” Paul Biondi, a former dealmaking executive at Bristol Myers Squibb and the president of the Pioneering Medicines initiative, said in a statement."


https://www.biopharmadive.com/news/pfizer-flagship-research-alliance-10-drugs-biondi/688144/
<< Previous
Bullboard Posts
Next >>